eli lilly q4 - Search News

Eli Lilly's Q4 2024 Earnings

Hosted on MSN · 17h

Eli Lilly stock down on Q4 guidance miss

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue guidance down 5%,

Barchart on MSN · 18h

Meta's Q4 2025 Earnings: What to Expect

Headquartered in Menlo Park, California, Meta Platforms, Inc. (META) is a global leader in technology and social connectivity, driving innovation through its digital platforms and immersive experiences.

Seeking Alpha on MSN · 22h

Eli Lilly issues Q4 2024 revenue guidance below consensus

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B, about $400M below the lower end of its recently issued financial guidance.

YAHOO!Finance · 21h

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.

Hosted on MSN · 2d

Eli Lilly's Q4 2024 Earnings: What to Expect

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressing medical needs.

18h

Eli Lilly Cuts Q4 Forecast Amid Weak Sales but Sees Bright 2025 with $61B Revenue Potential

Citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro, Eli Lilly ( NYSE:LLY) ...

19h

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Pharmaceutical Technology1h

JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

21h

Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees Growth In FY25

Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...

Finbold | Finance in Bold23m

Here’s why Eli Lilly stock is crashing

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

20hon MSN

Hims & Hers in focus as Eli Lilly obesity drug sales disappoint

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

Lilly trims sales forecast on weaker obesity/diabetes growth

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

13h

Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

19h

Eli Lilly Shares Down 7.5% as Market Reacts to Slashed Q4 Forecast

Shares of Eli Lilly ( NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results